APsense

  • Our Services

    We offer best-in-class research and consulting services pertaining to the markets of all geographies. Our experienced team of business analysts and consultants has mastered fundamental and advanced market research in diverse industries.

  • Syndicated Research

    Syndicated research is the most cost-effective market research approach, which gives an analytical outlook of the competitive positioning, product positioning, and size estimation of the market at the micro level. Our off-the-shelf reports offer key market insights that industry stakeholders require to base their business strategy on. Our syndicated research services empower our clients to meet diverse market objectives.

  • Customized Research

    we also deliver customized research services to address specific needs of our clients. With a vast pool of adroit analysts who are proficient in market research, we take pride in tailoring our research services to meet our clients’ definite requirements and aid their business growth.

  • Consulting Services

    Businesses, today, need to adapt themselves to the changes that transpire in the market. Staying abreast of the market trends, therefore, becomes imperative for accomplishing business objectives.

  • Our Vision

    To be the most trusted partner in our clients' success endeavors

Increasing Prevalence of Benign Prostatic Hyperplasia in American Men Driving Demand for BPH Treatment Procedures

Benign Prostatic Hyperplasia (BPH) is a medical condition in which the prostate gland becomes enlarged. The enlargement of the prostate gland causes urinary tract problems by blocking the flow of urine out of the body. This happens because the prostate gland surrounds the urethra, which is the tube that carries the urine from the urinary bladder to out of the body, and so, the enlargement of the gland squeezes or blocks the urethra, causing discomfort and problems while urinating.

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sample

In the U.S., the growing prevalence of this diseases, because of the surging geriatric population in the country, is rapidly becoming a major health issue. As a result, medical researchers are conducting extensive research and development (R&D) activities for developing advanced BPH treatment procedures. Moreover, the demand for BPH medications is also rising at an explosive pace in the country. Because of these factors, the U.S. benign prostatic hyperplasia (BPH) procedures market will advance rapidly in the coming years.

Amongst the various energy-based treatment procedures, the popularity of the laser-based procedures was found to be very high in the years gone by, because of the fact that these procedures are much more effective than the traditional treatment methods and are far less likely to cause various complications such as bleeding. There are many types of laser-based treatment procedures such as those involving thulium-, holmium lasers-, and green light lasers.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sample

Therefore, it can be said with complete certainty that the demand for benign prostatic hyperplasia treatment (BPH) procedures will rise enormously in the U.S. in the upcoming years, because of the growing prevalence of BPH in males and the rapid advancements and innovations being made in these procedures in the country.

Share:

How Increasing Number of Diabetic Patients are Augmenting Human Insulin Market Growth

On account of the growing number of diabetic patients, increasing geriatric population, technological advancements in insulin delivery devices, and rising population exposed to risk factors are leading to the growth of the human insulin market. The global market generated a revenue of $42.9 billion in 2017, and it is expected to witness a CAGR of 8.8% during the forecast period (2018–2023). Human insulin (HI) is synthetic insulin, which mimics the effects and functionality of natural insulin in humans. It is generally created by growing the insulin protein in the E. coli bacteria.

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/human-insulin-market/report-sample

In a recent P&S Intelligence research, the human insulin market is segmented by type, application, and region. Under the product segment, the market is further divided into HI drugs and delivery devices. Due to increase in research and development  activities for drugs discovery and manufacture, and high prevalence of diabetes, HI drugs held the larger share (79.5%) in the market in 2017 in terms of value. Furthermore, the rise in geriatric population and growth in demand for HI analogs is also pushing the market progress; analogs and biologics are two categories of the HI drugs division.


Globally, North America dominated the human insulin market in 2017 with 39.2% revenue share. An increase in the number of diabetes patients contributed in the growth of the domain. The number of diabetic patients had grown from 108 million to 422 million between 1980 and 2014, and this number is anticipated to reach 592 million by 2035. As per the International Diabetes Federation, in 2017, 425 million people aged 20–79 across the globe had diabetes, and this number is projected to reach 629 million by 2045.

Therefore, it is apparent that the steady growth of the market will give players lucrative opportunities to invest in the research and development of improved insulin drugs and delivery systems.

Read More...

Share:

Huge Boom Expected in Valuation of Global Protein Extracts from Single Cell Protein Sources Market till 2023

Soaring number of initiatives by governments and private organizations for creating awareness amongst the people about the health and environmental benefits of alternative protein sources is one of the major factors responsible for the rise in the demand for protein extracts from single cell protein sources across the world. For instance, Valensa International, which is a major producer of microalgae-based nutraceuticals launched an alliance with a U.S. based trade organization called Algae Biomass Organization (ABO) in 2017 in order to create awareness amongst the masses about the consumption of microalgae as an alternative protein source. 

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/protein-extracts-from-single-cell-protein-sources-market/report-sample


The surging population of livestock and cattle including sheep, goat, and buffalo, has boosted the production of animal feed, which has in turn, propelled the need for animal protein. As per the International Feed Industry Federation (IFIF), the total worldwide production of compound feed was recorded to be 1.0 billion tonnes in 2016. Therefore, it can be said that owing to the increasing production of compound feed, the production of protein from various alternative sources such as animals, microbes, and plants will also increase in future.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/send-enquiry?enquiry-url=protein-extracts-from-single-cell-protein-sources-market

Due to the above-mentioned factors, the revenue generated from the worldwide sales of protein extracts from single protein sources will increase from $5.3 billion to $8.7 billion from 2017 to 2023. Moreover, the global protein extracts from single cell protein sources market is predicted to advance at an 8.6% CAGR during the forecast period (2018–2023). There are various alternative sources of protein, such as yeast, fungi, bacteria, and algae. Amongst these, the utilization of algae-based protein sources is expected to record the fastest rise in the coming years. 

Therefore, it can be said with full surety that owing to the increasing consumption of protein by livestock, animals, and people and increasing awareness amongst the masses about alternative protein sources, the demand for protein extracts from single cell protein sources will boom in future.

Share:

How are Awareness Campaigns Driving Disposable Plastic Blood Bag Market?

Heart diseases kill 17.9 people each year, while 9.6 million die of cancer, says the World Health Organization (WHO). With these, the surgery and hospitalization rates are rapidly going up. One of the most basic things many such patients need is blood, which, being a highly critical and easily contaminable product, has to be kept in clean and sterile bags. Thus, with the growing incidence of chronic diseases and usage of blood at healthcare centers, the disposable plastic blood bag market is expanding around the world.

Receive Sample Copy of this Report:https://www.psmarketresearch.com/market-analysis/disposable-plastic-blood-bag-market/report-sample

Disposable bags are indispensable for two main reasons: to stop blood of different groups mixing with each other, which can be deadly for the recipient, and to minimize the chances of blood-borne diseases, such as acquired immune deficiency syndrome (AIDS). Disposable bags are also used when collecting blood, and with the rate of blood donation going up, the demand for such containers is also surging. For instance, in the U.K., the number of donated units increased from 161,019 in 2015/16 to 159.264 in 2018/19, according to the National Health Service (NHS) data.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/send-enquiry?enquiry-url=disposable-plastic-blood-bag-market

The primary reason behind the increase in blood donations is the continuous efforts by government and international organizations to raise the awareness about the same. Apart from the WHO, International Federation of Red Cross and Red Crescent Societies (IFRC) and American Red Cross are engaged in these activities. With campaigns and other activities organized by these agencies, people are realizing the importance of blood in patient treatment as well as the fact that donating blood regularly is good for their own health.

Across the world, the largest disposable plastic blood bag market is North America, majorly on account of the rising number of patients suffering from blood disorders. For instance, the Leukemia and Lymphoma Society says that every three minutes, blood cancer is diagnosed in one person in the U.S. Further, according to the National Cancer Institute of the U.S., 61,780 cases of leukemia were detected in the country and 2019, and the disease resulted in 22,840 deaths.

Hence, as the surgery and hospitalization rates increase and more people willingly donate blood, the demand for disposable plastic bags to store it will also rise.


Share:

Adrenocortical Carcinoma Therapeutics - Pipeline Analysis, Collaborations, and Other Developments


Adrenocortical carcinoma, also known as adrenal cortex carcinoma, is a rare form of cancer that occurs at the cortex layer of the adrenal gland. There are two adrenal glands present in the human body: one at the top of each kidney. Each adrenal gland is comprised of two distinct structures: the outer part of the adrenal glands (adrenal cortex) and the inner region (adrenal medulla).
Some of the genetic condition that can cause adrenocortical carcinoma are Li-Fraumeni syndrome, Carney complex, and Beckwith-Wiedemann syndrome. Some of the most common symptoms of this medical condition includes abdominal pain, lump in the abdomen, and feeling of fullness. 

Request to Get the Sample Pages at: 

The disease can be diagnosed by imaging technique such as computed tomography (CT) scan, magnetic resonance imaging (MRI), biopsy, blood tests, and urine tests. Millendo Therapeutics Inc. is in the process of developing ATR-101 as an acetyl CoA C-acetyltransferase inhibitor for the treatment of adrenocortical carcinoma. Merck & Co., Inc. is also in the process of developing pembrolizumab as a CD274 antigen inhibitor for the treatment of adrenocortical carcinoma. Some of the other companies and universities having the pipeline drug for adrenocortical carcinoma includes the Columbia University, Medunik Canada Inc., HRA Pharma, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Share:

Cathepsin K Inhibitors Therapeutics - Pipeline Analysis 2019 Clinical Trials & Results


Cathepsin K is a protease enzyme which is coded by CTSK gene. The function associated with the gene involves bone remodelling and resorption. Cathepsin K is a member of peptidase C1 protein family and expressed mainly in osteoclasts. The protein has high specificity for kinins and has the capability to catabolize collagen, elastin, and gelatin. Cathepsin K is found to be over-expressed in cancer such as breast cancer and glioblastoma. The mutation in CTSK gene can cause pycnodysostosis. Due to over expression of cathepsin K in osteoclasts, bone deformation occurs which leads to osteoporosis.


Company like Medivir AB is in the process of developing MIV-711 as a cathepsin K inhibitor for the treatment of osteoarthritis. Amura Holdings Ltd., and Merck & Co. Inc. are some other companies having pipeline of cathepsin K inhibitors.
Request to Get the Sample Pages at:  
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.



Share:

Adenosine 5-Monophosphate Activated Protein Kinase (AMPK) Modulators Therapeutics - Pipeline Analysis 2018


Adenosine 5-monophosphate activated protein kinase (AMPK) plays an important role in regulation of homeostasis. Dysregulation of AMPK can result in many diseases which includes obesity and type 2 diabetes. Several studies have also suggested that AMPK are also associated with the development of neurological diseases and cancer.
Esperion Therapeutics Inc. is in the process of developing Bempedoic acid as a small molecule which acts as an AMPK stimulant for the treatment of hypercholesterolemia, dyslipidaemia, and hypertension. Betagenon AB, Boehringer Ingelheim International GmbH, and Poxel SA are some other companies having pipeline AMPK modulators for the management of several diseases.

Request to Get the Sample Pages at:  


The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

Share:

Popular Posts

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages